TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Clene to Provide CNM-Au8® ALS Program Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kevin Gardner
Clene to Provide CNM-Au8® ALS Program Update

Clene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.

Insights
WMT   neutral

Mentioned as an example of a company that has previously conducted a stock split


CLNN   neutral

The company is presenting ongoing research and development in a clinical-stage program, indicating progress but without definitive breakthrough claims